Justin J. Hasford
Partner
Justin Hasford has experience in all areas of intellectual property law. His practice focuses on complex patent litigation at the trial and appellate levels on behalf of pioneer pharmaceutical companies. He has particular experience with cases arising from Abbreviated New Drug Applications (ANDAs) under the Hatch-Waxman Act and in post-grant proceedings before the Patent Trial and Appeal Board (PTAB). Justin has also litigated trade secret, antitrust, and business method patent cases.
Experience in Life Sciences
Eye Therapies, LLC v. Slayback Pharma, LLC
Finnegan represented Bausch & Lomb’s licensee Eye Therapies, LLC in an appeal at the U.S. Court of Appeals for the Federal Circuit from a Patent Trial and Appeal Board (PTAB) decision finding Eye Therapies’ patent directed to a low-dose brimonidine treatment for eye redness (Lumify®) to be unpatentable. In a precedential decision, the Federal Circuit agreed with Finnegan’s arguments and found that the Board had wrongly invalidated the patent based on an incorrect claim construction, vacating and remanding the case back to the PTAB. The proceeding settled shortly thereafter
23-2173, Fed. Cir., Judges Taranto, Stoll, Scarsi
Successfully represented Bausch & Lomb and Eye Therapies in a Hatch-Waxman patent infringement litigation and parallel PTAB challenges concerning an ANDA for generic versions of over-the-counter Lumify® ocular drops. The cases settled favorably for our clients.
3:21-cv-16766, D.N.J., Judges Kirsch, Singh
IPR2022-00146, PTAB, Judges Hulse, New, Pollock
IPR2024-00467, PTAB, Judges Flax, Pollock, Yang
IPR2022-00142, PTAB, Judges Flax, Hulse, New, Pollock
Bausch Health Ireland Limited et al. v. Aurobindo Pharma Limited et al.
Represented Bausch Health et al. in Abbreviated New Drug Application (ANDA) litigation involving Trulance® (plecanatide) tablets for the treatment of irritable bowel syndrome and chronic idiopathic constipation, resulting in favorable settlement post-trial.
2:23-cv-00170, D.N.J., Judge Chesler
1:21-cv-00611, D. Del., Judge Stark
1:22-cv-00085, N.D.W. Va., Judge Kleeh
2:21-cv-00573, W.D. Pa., Judges Cercone, Hardy
1:22-cv-00020, N.D.W. Va., Judge Kleeh
2:21-cv-10057, D.N.J., Judge Chesler
2:21-cv-10403, D.N.J., Judge Chesler
2:23-cv-03333, D.N.J., Judge Chesler
1:24-cv-00036, N.D.W. Va., Judge Kleeh
2:24-cv-07182, D.N.J., Judge Chesler
2:24-cv-11179, D.N.J., Judge Chesler
1:25-cv-00003, N.D.W. Va., Judge Kleeh
IPR2023-00016, PTAB, Judges Hardman, Hulse, Valek
IPR2022-00722, - 01102, -01103, -01104, -01105, PTAB, Judges Hardman, Hulse, Snedden, Valek
Mitsubishi Tanabe Pharma Corporation v. Shanghai Auzone Biological Technology Co., Ltd et al.
Representing Mitsubishi Tanabe Pharma in litigation matters related to Radicava ORS (edaravone) used to treat patients with amyotrophic lateral sclerosis (ALS).
2:25-cv-03326, D.N.J., Judge Cecchi
1:23-cv-00759, D. Del., Judges Burke, Connolly, Hall
1:24-cv-01423, D. Del., Judge Hall
1:24-cv-00549, D. Del., Judge Hall
Bausch & Lomb Incorporated; Bausch & Lomb Ireland Limited; Nicox, SA v. Gland Pharma Limited, et al.
Representing Bausch & Lomb in ANDA litigation involving Vyzulta® (latanoprostene bunod) eye drops for reduction of intraocular pressure (IOP) in patients suffering from glaucoma or ocular hypertension. Bausch & Lomb sought to protect the Vyzulta® franchise against challenges asserted by generic pharmaceutical manufacturers Dr. Reddy’s and Gland.
3:22-cv-04345, D.N.J., Judges Chesler, Kirsch, Shipp
3:23-cv-03463, D.N.J., Judge Kirsch
Arvinas Operations, Inc. et al. v. Qian et al.
Defending Accutar Biotechnology, Inc. in a trade secret lawsuit brought by Arvinas regarding alleged trade secrets concerning breast cancer therapies.
3:22-cv-00717, D. Conn., Judges Chatigny, Richardson
Insights on Life Sciences
Webinar
March 12, 2026
Webinar
Webinar
Protect Your Innovations: Recent Patent Case Law in the Life Sciences
February 11, 2026
Webinar
Webinar
February 18, 2025
Webinar
Webinar
December 14, 2023
Webinar
Professional Recognition
“Justin Hasford…is especially effective in aligning PTAB and district court strategies.”
News on Life Sciences
Award/Ranking
Seven Finnegan Partners Named to IAM Strategy 300 Global Leaders 2026
November 19, 2025
Intellectual Asset Management (IAM)Award/Ranking
Eleven Finnegan Attorneys Named to the 2025 IAM Strategy 300 Global Leaders List
November 20, 2024
Intellectual Asset Management (IAM)Award/Ranking
Eleven Finnegan Attorneys Named to the 2024 IAM Strategy 300 List
August 14, 2024
Intellectual Asset Management (IAM)Award/Ranking
10 Finnegan Attorneys Named to the 2023 IAM Strategy 300 List
October 5, 2023
Intellectual Asset Management (IAM)Press Release
Finnegan Victory for BioDelivery Sciences International in ANDA Case Affirmed
December 29, 2022
Professional Activities
- American Chemical Society, Chemistry and the Law Division
(immediate past chair, 2009; chair-elect, 2007; chair, 2008; alternate councilor, 2016-present; archivist, 2016-present; co-secretary, 2011-2015; program chair, 2009-2010; program chair, 2005-2007) - American Bar Association
- American Intellectual Property Law Association
- District of Columbia Bar
- Virginia Bar Association
Admissions
- U.S. Patent and Trademark Office
- New Jersey
- District of Columbia
- Virginia
- U.S. District Court, W.D. Texas
- U.S. District Court, District of Columbia
- U.S. District Court, D. New Jersey
- U.S. Court of Appeals, D.C. Circuit
- Supreme Court of the United States
- U.S. District Court, W.D. Virginia
- U.S. Court of Appeals, Federal Circuit
- U.S. District Court, E.D. Virginia
- U.S. District Court, W.D. Tennessee
Education
- University of Virginia School of Law
- J.D., 2003
- Vanderbilt University
- B.S., Chemistry, with high honors, and Molecular Biology, magna cum laude, 1998
Justin's Practices
- Global IP Enforcement, Litigation, and Trials
- Branded Hatch-Waxman (ANDA) Litigation and Trials
- Patent Litigation and Trials
- Patent Office Invalidation Proceedings
- Ex Parte Reexamination (EPR)
- PTAB Invalidation Proceedings: IPR and PGR
- Prosecution and Portfolio Management
- Due Diligence
- Ex Parte Reexamination (EPR)
- Opinions and Counseling
Justin's Industries
- Chemicals, Industrials, and Materials
- Chemical
- Life Sciences
- Biotechnology
- Digital Health
- Pharmaceutical